PARP抑制剂对恶性肿瘤放疗增敏作用的研究进展  

Research progress on radiotherapy sensitization of PARP inhibitors in the radiotherapy of malignant tumors

作　　者：查昳琳 顾文栋[1] Zha Yilin;Gu Wendong(Department of Radiotherapy Oncology,the First People's Hospital of Changzhou,Changzhou 213000,China)

机构地区：[1]常州市第一人民医院肿瘤放射治疗科,常州213000

出　　处：《国际放射医学核医学杂志》2024年第7期441-448,共8页International Journal of Radiation Medicine and Nuclear Medicine

摘　　要：聚腺苷二磷酸核糖聚合酶抑制剂(PARPi)是重要的抗肿瘤靶向药物之一,目前主要应用于卵巢癌等恶性肿瘤的治疗。PARPi可提高放疗在多种恶性肿瘤中的疗效。笔者就PARPi在恶性肿瘤治疗中作为放射增敏剂的临床前和临床研究进展进行综述,为临床使用PARPi作为放疗增敏剂提供依据。Poly(adenosine diphosphate-ribose)polymerase inhibitor(PARPi)are one of the important anti-tumor targeting drugs,which is mainly used in the treatment of ovarian cancer and other malignant tumors.In recent years,studies have shown that PARPi can increase the efficacy of radiotherapy in many types of malignant tumors.The aruthors review the preclinical and clinical progresses of PARPi as radiosensitizers in the treatment of malignant tumors,providing evidence for clinical use of PARPi as radiosensitizer.

关 键 词：多(ADP核糖)聚合酶抑制剂 放射疗法 肿瘤 放疗增敏剂 

分 类 号：R730.55[医药卫生—肿瘤]